8-K: Unicycive Therapeutics Implements 1-for-10 Reverse Stock Split to Meet Nasdaq Listing Requirements

Unicycive Therapeutics, Inc. has enacted a 1-for-10 reverse stock split, effective June 18, 2025, to increase its common stock's bid price and regain compliance with Nasdaq's minimum listing requirement.

Summary

• Unicycive Therapeutics, Inc. has implemented a 1-for-10 reverse stock split of its common stock.
• The reverse stock split became effective at 4:01 p.m. Eastern Time on June 18, 2025, following the filing of a Charter Amendment with the Delaware Secretary of State.
• Common stock began trading on a split-adjusted basis on the Nasdaq Capital Market at the opening of trading on June 20, 2025, under the existing symbol UNCY, with a new CUSIP number (90466Y 202).
• The primary purpose of the reverse stock split is to increase the bid price of the common stock to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• Every 10 shares of common stock were automatically reclassified and combined into one share.
• No fractional shares were issued; instead, fractional interests were rounded up to the next whole share after aggregation.
• The reverse stock split uniformly affects all stockholders, without changing percentage ownership or proportionate voting power, except for immaterial changes from fractional share treatment.
• The number of authorized shares and the par value per share remain unchanged.
• The number of issued and outstanding shares of common stock was reduced from approximately 126,409,281 to approximately 12,768,239.
• Proportionate adjustments will be made to the per share exercise prices and number of shares underlying outstanding stock options, stock incentive plans, warrants, and the conversion price of Series A-2 preferred stock.

Sentiment

Score: 3

Explanation: The sentiment is largely negative because a reverse stock split is typically a reactive measure to avoid delisting due to a low stock price, indicating underlying challenges. While it addresses a compliance issue, it doesn't fundamentally improve the company's financial health or prospects. The positive is that it's a necessary step to maintain listing, but the context is unfavorable.

Positives

• The reverse stock split is a necessary step to regain compliance with Nasdaq's minimum bid price requirement, which is crucial for maintaining the company's listing on a major exchange.
• The company's stockholders approved the board's authority to effect the reverse split, indicating alignment on this strategic move.

Negatives

• A reverse stock split is typically undertaken by companies whose stock price has fallen significantly, often signaling underlying financial or operational challenges.
• The need for a reverse split indicates that the company's stock price was below the Nasdaq minimum bid price requirement, posing a risk of delisting.
• While the split aims to increase the per-share price, it does not fundamentally change the company's market capitalization or intrinsic value.
• There is no guarantee that the reverse split will successfully maintain the stock price above the Nasdaq minimum bid requirement long-term.

Risks

• Delisting Risk: The primary risk is that the reverse stock split may not result in the common stock maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading sessions, potentially leading to Nasdaq suspending trading or delisting the Company's common stock.
• Market Perception: Reverse stock splits can sometimes be perceived negatively by investors, potentially leading to further selling pressure.
• Liquidity: While the number of shares decreases, the overall market capitalization remains the same, but the reduced number of shares could potentially impact liquidity for some investors.
• Operational Challenges: The need for a reverse split often points to underlying operational or financial challenges that have led to a depressed stock price.

Future Outlook

The Company anticipates that the reverse stock split will increase its common stock's bid price, enabling it to regain compliance with Nasdaq's minimum bid price requirement for continued listing. However, there is a risk that Nasdaq may not process the split on the expected timeline, or that the stock price may not remain above $1.00 per share for the required period, potentially leading to a suspension of trading or delisting.

Management Comments

• The Board determined to effect a reverse split of the Common Stock (the Reverse Stock Split) at a ratio of 1-for 10.
• The Company issued a press release announcing the Reverse Stock Split.
• Shalabh Gupta, Chief Executive Officer, signed the report on behalf of Unicycive Therapeutics, Inc.

Industry Context

Reverse stock splits are a common strategy employed by biotechnology companies, particularly clinical-stage ones like Unicycive Therapeutics, when their stock price falls below exchange minimums. This action is typically a defensive measure to maintain listing on a major exchange like Nasdaq, which is critical for liquidity, investor confidence, and access to capital markets. While it addresses a technical listing requirement, it does not inherently improve the company's underlying business fundamentals or clinical pipeline progress. The biotech industry often sees volatile stock prices due to the high-risk, high-reward nature of drug development, making compliance with listing rules a recurring challenge for some smaller firms.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism used by companies across various industries, including biotechnology, to meet stock exchange listing requirements, particularly minimum bid price rules.
• The 1-for-10 ratio chosen by Unicycive is within the typical range (often 1-for-2 to 1-for-20 or higher) seen in similar situations for companies aiming to significantly boost their per-share price.
• The rounding up of fractional shares is a common practice that benefits small shareholders by ensuring they receive a whole share rather than cash for a fractional interest, which can be administratively simpler and more favorable than rounding down or cashing out.
• Companies like Sorrento Therapeutics (SRNE) and Athersys (ATHX) have also undertaken reverse stock splits in recent years to address similar Nasdaq compliance issues, highlighting this as a recurring event for companies facing stock price challenges.
• The immediate impact on market capitalization and proportionate ownership (excluding fractional share treatment) is consistent with how reverse splits are structured across the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: All shareholders will see their number of shares reduced by a factor of 10, with their proportionate ownership remaining largely unchanged (except for minor adjustments due to fractional share rounding up). The goal is to increase the per-share price, potentially making the stock more attractive to institutional investors and maintaining its Nasdaq listing.
• Employees: Employees holding stock options or awards under incentive plans will have their per-share exercise prices and number of underlying shares proportionately adjusted, ensuring their equity incentives retain equivalent value.
• Creditors: No direct impact mentioned, but maintaining Nasdaq listing can be important for a company's overall financial stability and access to future financing, which indirectly benefits creditors.
• Customers/Suppliers: No direct impact on customers or suppliers as the action is financial/corporate governance related, not operational.

Next Steps

• The Company's common stock will continue to trade on a split-adjusted basis on the Nasdaq Capital Market under the symbol UNCY.
• The Company will need to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading sessions to regain compliance with Nasdaq's listing requirements.
• The Company will continue its clinical development programs for oxylanthanum carbonate and UNI-494.

Key Dates

Recommendation

Keywords

Unicycive Therapeutics, UNCY, Reverse Stock Split, Nasdaq Capital Market, Stock Compliance, Biotechnology, Kidney Disease, Hyperphosphatemia, Oxylanthanum Carbonate, UNI-494, SEC Filing, 8-K, Corporate Governance